Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension

Objective To assess the sustained, long-term efficacy of bimekizumab in improving patient symptoms and health-related quality of life (HRQoL) in axial spondyloarthritis (axSpA) to 3 years.Methods Both BE MOBILE 1 (non-radiographic axSpA) and 2 (radiographic axSpA) comprised a 16-week double-blind, p...

Descrición completa

Gardado en:

Detalles Bibliográficos
Principais autores:	Atul Deodhar, Philip J Mease, Uta Kiltz, Karl Gaffney, Helena Marzo-Ortega, Maureen Dubreuil, Victoria Navarro-Compán, Sarah Kavanagh, Christine de la Loge, Chetan Prajapati
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMJ Publishing Group 2026-05-01
Series:	RMD Open
Acceso en liña:	https://rmdopen.bmj.com/content/12/2/e006670.full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension

Títulos similares